Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Boan Biotech Starts China Trial of Anti-CD25 Antibody for Solid Tumor Cancers

publication date: Feb 13, 2023

Boan Biotech, a Luye Pharma subsidiary that develops novel antibodies, has dosed the first patient in a China Phase I trial of its anti-CD25 antibody in patients with solid tumor cancers. BA1106 is an investigational non-IL-2 blocking anti-CD25 antibody that Boan believes has promising anticancer potential to treat cancers with high expression of CD25, a broad spectrum of possible indications. BA1106 is the first investigational anti-CD25 antibody to start clinical trials in China. Boan says it has been speeding up its novel antibody development, focusing on oncology and autoimmune diseases. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital